Solid tumor or hematological malignancy
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged between 18 and 65 years; 2. Diagnosed with solid tumor or hematological malignancy; 3. Absolute neutrophil count (ANC) < 0.5 × 10?/L; 4. Meeting diagnostic criteria for sepsis; 5. Provision of signed informed consent form with commitment to full trial participation;
Exclusion criteria
Exclusion criteria: 1. Patients with non-cancerous immunodeficiencies (e.g., HIV infection, primary immunodeficiency disorders, solid organ transplant recipients, hematopoietic stem cell transplant recipients); 2. Active autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus); 3. High-dose corticosteroid use (>=200 mg/day hydrocortisone equivalent) within 72 hours; 4. Receiving T-cell therapies (e.g., CAR-T) or treatment for graft-versus-host disease (GVHD) post-transplant; 5. Immune checkpoint inhibitor administration within 4 weeks prior; 6. Patients requiring continuous renal replacement therapy (CRRT) or extracorporeal membrane oxygenation (ECMO); 7. Pregnant or lactating patients; 8. Life expectancy <72 hours or patients transitioned to palliative care only;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma/Serum Cytokine & Chemokine Profiling;Immune Checkpoint Molecule Expression;Comprehensive Profiling of Peripheral Blood Immune Cell Subsets: Phenotypic Proportions and Functional Activation Status;Monocytic HLA-DR Density (mHLA-DR);Gut Microbiome Profiling; | — |
Countries
China
Contacts
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology